Characterizing the clinical relevance and the mechanism underlying TRIB2-mediated drug resistance to MEK inhibitiors in the context of melanoma

Project Information

TRIBBLES

Grant agreement ID: 748585

DOI 10.3030/748585

Project closed

EC signature date 6 March 2017

Start date 1 September 2018

End date 31 August 2020

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost € 160 635,60

EU contribution € 160 635,60

Coordinated by

UNIVERSIDADE DO ALGARVE
Portugal

Objective

Melanoma is the most aggressive form of skin cancer resistant to all standard therapies. Currently, the established treatment of metastatic melanoma includes dacarbazine (DTIC) administration associated with response rates of between 10-20% with severe side effects during treatment. Recently, the BRAF inhibitors (vemurafenib and dabrafenib) and the MEK inhibitor (trametinib) were approved for the treatment of melanoma patients with mutated BRAF (about 50% of patients) while there are several PI3K, AKT, mTOR and MEK inhibitors being tested in clinical trials. However, the effectiveness of all these treatment modalities is limited by intrinsic or acquired resistance. The host lab has discovered a novel mechanism of resistance to a broad spectrum of drugs in clinical trials/use for melanoma therapy mediated by the kinase-like protein TRIB2. This means that TRIB2 could be used as a biomarker to select melanoma patients for specific treatment options and to develop co-treatment strategies to overcome drug resistance. This project pretends to (1) understand the mechanisms underlying TRIB2-mediated resistance to MEK inhibitors and to (2) further develop TRIB2 as a prognostic and predictive biomarker for melanoma. Ultimately, the expected results will be highly relevant for the clinic as they might allow to select melanoma patients for specific treatment options and to develop co-treatment strategies to overcome TRIB2 mediate resistance.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

• medical and health sciences › clinical medicine › oncology › skin cancer › melanoma
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance

You need to log in or register to use this function

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2016 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2016

Funding Scheme

MSCA-IF-EF-RI - RI – Reintegration panel

Coordinator

UNIVERSIDADE DO ALGARVE

• Net EU contribution: € 160 635,60
• Address: CAMPUS DE PENHA ; 8005 139 Faro ; Portugal
• Region: Continente › Algarve › Algarve
• Activity type: Higher or Secondary Education Establishments
• Total cost: € 160 635,60